**All Interactions with Tenofovir disoproxil fumarate (Viread)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Tenofovir disoproxil fumarate** | **Effect on Drug Levels** | **Effect on Tenofovir disoproxil fumarate Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Abacavir[135](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#135)  (ABC)(Ziagen) | 300 mg BID | 300 mg QD x 13 days | No significant change | No significant change | - | - | No dose adjustment necessary |
| Adefovir[235](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#235)  (Hepsera) | 10 mg QD | 300 mg QD x 1 dose | - | No significant change | - | - | No dose adjustment necessary |
| Atazanavir[155](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#155)  (ATV)(Reyataz) | 300 mg QD with 100 mg ritonavir QD x 10 d | 300 mg QD x 10 d, separated 12 hours away from atazanavir/ritonavir | Atazanavir Cmin: decreased 20% | Tenofovir AUC: increased 37%; Cmax: increased 34%; Cmin: increased 29% | Increased tenofovir effects | - | Coadminister atazanavir/ritonavir together with tenofovir |
| Atazanavir[148](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#148)  (ATV)(Reyataz) | 300 mg QD with ritonavir 100 mg QD | 300 mg QD | Atazanavir AUC: no significant change; Cmax: no significant change; Cmin: decreased 21% (compared to atazanavir 300 QD with ritonavir 100 mg QD)Ritonavir AUC: increased 20%; Cmax: no signficant change; Cmin: no significant change | - | - | Unknown | No dose adjustment necessary |
| Atazanavir[8](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#8),[9](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#9),[10](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#10)  (ATV)(Reyataz) | 300 mg QD with ritonavir 100 mg QD on days 1-42 | 300 mg QD on days 15-42 | Atazanavir Cmax: decreased 28%; AUC: decreased 25%; Cmin: decreased 26%; Ritonavir Cmax: decreased 28%; AUC: decreased 25%; Cmin: no significant change | Not studied | Decreeased atazanavir effects; possibly increased tenofovir effects | - | Do not coadminister with unboosted atazanavir (400 mg); Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Tenofovir disoproxil fumarate** | **Effect on Drug Levels** | **Effect on Tenofovir disoproxil fumarate Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Atazanavir[155](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#155)  (ATV)(Reyataz) | 400 mg QD with 100 mg ritonavir QD x 10 d | 300 mg QD x 10 d | Atazanavir AUC: increased 38%; Cmax: increased 31%; Cmin: increased 33% | Tenofovir AUC: increased 55%; Cmax: increased 39%; Cmin: increased 70% | Increased atazanavir and tenofovir effects | - | Do not coadminister |
| Atazanavir[9](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#9),[123](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#123),[124](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#124),  (ATV)(Reyataz) | 400 mg QD with a light meal | 300 mg QD with a light meal | Atazanavir AUC: decreased 26%; Cmax: decreased 24%; Cmin: decreased 40% | Tenofovir AUC: increased 25%; Cmax: no significant change | Decreased atazanavir effects; increased tenofovir effects | Unknown | Do not coadminister with unboosted atazanavir (400 mg); Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen |
| Boceprevir[569](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#569)  (Victrelis) | 800 mg TID x 7 days | 300 mg QD x 7 days | No significant effect | Tenofovir Cmax: increased 32% | - | - | No dose adjustment necessary |
| Buprenorphine[443](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#443)  (Suboxone)(Buprenex) | 16 mg QD | 300 mg QD | No significant change | - | - | - | No dose adjustment necessary |
| Daclatasvir[747](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#747)  (Daklinza) | 60 mg daily | 300 mg daily | Daclatasvir AUC increased 10%; Cmin increased 15% | - | - | - | No dose adjustment necessary |
| Darunavir[161](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#161)  (DRV)(Prezista) | 300 mg BID with ritonavir 100 mg BID | 300 mg QD | Darunavir AUC: increased 21%; Cmax: increased 16%; Cmin: increased 24% | Tenofovir AUC: increased 22%; Cmax: increased 24%; Cmin: increased 37% | Possibly increased darunavir effects; possibly increased tenofovir effects | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Tenofovir disoproxil fumarate** | **Effect on Drug Levels** | **Effect on Tenofovir disoproxil fumarate Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Didanosine[143](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#143)  (ddI)(Videx) | - | - | - | - | Potential early virologic failure | - | Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients |
| Didanosine[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96)  (ddI)(Videx) | 250 mg or 400 mg (buffered formulation) QD x 7 days | 300 mg QD | Didanosine AUC: increased 44%; Cmax: increased 28% | No significant change | Increased didanosine effects | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| Didanosine[103](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#103)  (ddI)(Videx) | 250 mg QD (enteric coated) x 1 (given with food, without food and staggered by 2 hours) | 300 mg QD x 9 days | Didanosine AUC: no significant change (fed); Cmax: no significant change; Didanosine AUC: no significant change (staggered); Cmax: no significant change (staggered); Didanosine AUC: no significant change (fed); Cmax: decreased 29% (fed)All values compared to 400 mg QD (enteric coated) reference dose. | No significant change | - | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| Didanosine[97](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#97),[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96)  (ddI)(Videx) | 400 mg (buffered formulation) QD x 7 days | 300 mg QD x 7 days | Didanosine AUC: increased 44%; Cmax: increased 28% | No significant change | Increased didanosine effects | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| Didanosine[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96),[102](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#102)  (ddI)(Videx) | 400 mg (enteric coated capsule) x 1 dose | 300 mg QD | Didanosine AUC: increased 48% (fasted); Cmax: increased 48% (fasted)Didanosine AUC: increased 60% (fed); Cmax: increased 64% (fed) | No significant change | Increased didanosine effects | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| Didanosine[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96)  (ddI)(Videx) | 400 mg QD (enteric coated) x 7 days (given with food) | 300 mg QD | - | - | Increased didanosine effects | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Tenofovir disoproxil fumarate** | **Effect on Drug Levels** | **Effect on Tenofovir disoproxil fumarate Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Didanosine[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96)  (ddI)(Videx) | 400 mg QD (enteric coated) x 7 days (given without food) | 300 mg QD | Didanosine AUC: increased 48%; Cmax: increased 28% | Not studied | Increased didanosine effects | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| Dolutegravir[641](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#641)  (Tivicay) | 50 mg QD | 300 mg QD | No significant change | TDF AUC: increased 12%; Cmin: increased 19% | - | - | No dose adjustment necessary |
| Efavirenz[143](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#143)  (EFV)(Sustiva) | - | - | - | - | Potential early virologic failure | - | Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients |
| Efavirenz[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96),[98](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#98)  (EFV)(Sustiva) | 600 mg QD x 14 days | 300 mg QD x 7 days | No significant change | No significant change | - | - | No dose adjustment necessary |
| Emtricitabine[125](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#125),[126](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#126)  (FTC)(Emtriva) | 200 mg QD x 7 days | 300 mg QD x 7 days | No significant change | No significant change | - | - | No dose adjustment necessary |
| Emtricitabine[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96)  (FTC)(Emtriva) | 200 mg QD x 7 days | 300 mg QD | No significant change | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Tenofovir disoproxil fumarate** | **Effect on Drug Levels** | **Effect on Tenofovir disoproxil fumarate Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Entecavir[391](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#391)  (Baraclude) | - | - | No significant change | No significant change | - | - | No dose adjustment necessary |
| Ethinyl estradiol/norethindrone acetate[367](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#367)  (others)(Ortho-Novum) | 1 tab QD | 300 mg QD | No significant change | No significant change | - | - | No dose adjustment necessary |
| Ethinyl estradiol/norgestimate[430](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#430)  (others)(Ortho Tri-Cyclen, Ortho Tri-Cyclen) | 1 tab QD | 300 mg QD | Ethinyl estradiol: no significant effect; Deacetyl norgestimate: no significant effect | - | - | - | No dose adjustment necessary |
| Etravirine[429](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#429)  (ETR)(Intelence) | 200 mg BID | 300 mg QD | Etravirine AUC: decreased 19%; Cmin: decreased 18%; Cmax: decreased 19% | Tenofovir AUC: increased 15%; Cmin: increased 19%; Cmax: increased 15% | - | - | No dose adjustment necessary |
| Fosamprenavir[153](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#153)  (FPV)(Lexiva) | 1400 mg with 100 mg ritonavir QD x 14 days | 300 mg QD | Amprenavir AUC: no significant change; Cmax: no significant change; Cmin: increased 24% | No significant change | - | - | No dose adjustment necessary |
| Fosamprenavir[153](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#153)  (FPV)(Lexiva) | 1400 mg with 200 mg ritonavir QD x 14 days | 300 mg QD | No significant change | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Tenofovir disoproxil fumarate** | **Effect on Drug Levels** | **Effect on Tenofovir disoproxil fumarate Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Indinavir[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96),[98](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#98)  (IDV)(Crixivan) | 800 mg TID x 7 days | 300 mg QD x 7 days | No significant change | No significant change | - | - | No dose adjustment necessary |
| Lamivudine[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96),[97](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#97)  (3TC)(Epivir) | 150 mg BID x 7 days | 300 mg QD x 7 days | Lamivudine Cmax: decreased 24% | No significant change | - | - | No dose adjustment necessary |
| Ledipasvir/sofosbuvir[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#727),[713](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#713) | Ledipasvir 90 mg with sofosbuvir 400 mg QD | 300 mg QD | - | TDF AUC ↑ 40%-98% when TDF co-administered with rilpivirine and efavirenz. Further ↑ TDF possible if co-administered with protease inhibitors. | - | - | No dose adjustment necessary, consider renal function and avoid use if CrCl <60 ml/min. Monitor for TDF toxicity |
| Lopinavir/ritonavir[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96),[98](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#98)  (LPV/r)(Kaletra) | 400 mg/100 mg BID x 14 days | 300 mg QD | Lopinavir AUC: decreased 15%; Cmax: decreased 15%; Cmin: no significant change; Ritonavir AUC: decreased 24%; Cmax: decreased 28%; Cmin: no significant change | Tenofovir AUC: increased 34%; Cmax: increased 31%; Cmin: increased 29% | Increased tenofovir effects | - | No dose adjustment necessary |
| Lopinavir/ritonavir[104](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#104)  (LPV/r)(Kaletra) | 400/100 mg BID | 300 mg QD | Lopinavir: no significant change. Ritonavir: no significant change | Not studied | - | - | No dose adjustment necessary |
| Lopinavir/ritonavir[78](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#78),[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96)  (LPV/r)(Kaletra) | 400/100 mg BID | 300 mg QD | No significant change | Tenofovir AUC: increased 32%; Cmin: increased 51%; half-life: no significant change | Possibly increased tenofovir effects | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Tenofovir disoproxil fumarate** | **Effect on Drug Levels** | **Effect on Tenofovir disoproxil fumarate Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Methadone[185](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#185)  (Dolophine) | 40-110 mg/day | 300 mg QD | No significant change | Not reported | - | - | No dose adjustment necessary |
| Methadone[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96),[188](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#188)  (Dolophine) | stable dose (range 45-130 mg) QD | 300 mg QD on days 2-15 | R-methadone: no significant change;S-methadone: no significant change;total methadone: no significant change | Not studied | - | - | No dose adjustment necessary |
| Nevirapine[143](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#143)  (NVP)(Viramune) | - | - | - | - | Potential early virologic failure | - | Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment naive patients |
| Probenecid[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#96)  (Benemid)(Benemid) | - | - | No significant change | Increased tenofovir levels | Increased tenofovir effects | Probenecid-induced inhibition of the renal tubular secretion of tenofovir | Avoid combination |
| Raltegravir[3](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#3)  (RAL)(Isentress) | 400 mg BID | 300 mg QD | Raltegravir AUC: increased 49%; Cmax: increased 64% | - | Possibly increased raltegravir effects | - | No dose adjustment necessary |
| Ribavirin[235](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#235)  (Rebetol, Virazole) | 800 mg QD | 300 mg QD x 1 dose | - | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Tenofovir disoproxil fumarate** | **Effect on Drug Levels** | **Effect on Tenofovir disoproxil fumarate Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Rifampin[348](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#348),[349](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#349)  (Rifampicin)(Rifadin) | 600 mg QD on days 11-21 | 300 mg QD on days 1-20 | No significant change | No significant change | - | - | No dose adjustment necessary |
| Rilpivirine[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#567)  (RPV)(Edurant) | 150 mg QD | 300 mg QD | No significant change | Tenofovir AUC: increased 23%; Cmin: increased 24%; Cmax: increased 19% | Potentially increased tenofovir effects | - | No dose adjustment necessary |
| Saquinavir[149](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#149)  (SQV)(Fortovase, Invirase) | 1000 mg (hard gel caps) with ritonavir 100 mg BID on days 1-14 | 300 mg QD on days 3-14 | Saquinavir AUC: no significant change; Cmax: no significant change; Cmin: no significant changeRitonavir AUC: no significant change; Cmax: no significant change; Cmin: increased 27% | Not studied | - | - | No dose adjustment necessary |
| Saquinavir[142](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#142)  (SQV)(Fortovase, Invirase) | 1000 mg BID with 100 mg ritonavir on days 1-14 | 300 mg QD on days 2-14 | No significant change either for saquinavir or ritonavir | No significant change | - | - | No dose adjustment necessary |
| Saquinavir[145](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#145)  (SQV)(Fortovase, Invirase) | 1000 mg saquinavir BID with 100 mg ritonavir BID | 300 mg QD | Saquinavir AUC: increased 29%; Cmax: increased 22%; Cmin: incresed 47% | Tenofovir Cmin: increased 23% | - | - | No dose adjustment necessary |
| Simeprevir[679](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#679)  (Olysio) | 150 mg QD x 7 days | 300 mg QD x 7 days | Simeprevir AUC: decreased 24%; Cmax: decreased 15% | Tenofovir AUC: increased 18%; Cmax: increased 19%; Cmin: increased 24% | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Tenofovir disoproxil fumarate** | **Effect on Drug Levels** | **Effect on Tenofovir disoproxil fumarate Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Sofosbuvir[659](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#659)  (Sovaldi) | 400 mg x 1 | 300 mg QD | Sofosbuvir Cmax increased 25% | - | - | - | No dose adjustment necessary |
| Stavudine[12](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#12)  (d4T)(Zerit) | 100 mg extended release x 1 dose | 300 mg QD x 7 days | No significant change | Not studied | - | - | No dose adjustment necessary |
| Stavudine[136](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#136)  (d4T)(Zerit) | 100 mg XR QD on days 1 and 9 | 300 mg QD on days 2-9 | - | No significant change | - | - | No dose adjustment necessary |
| Telaprevir[571](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#571)  (Incivek) | 1125 mg Q8H x 7 days | 300 mg QD administered with 600 mg efavirenz QD x 7 days | Telaprevir AUC: decreased 18%; Cmin: decreased 25% | Tenofovir Cmin: increased 17%; Cmax: increased 22% | Possibly increased tenofovir effects | - | No dose adjustment necessary |
| Telaprevir[571](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#571)  (Incivek) | 1500 mg Q12H x 7 days | 300 mg QD administered with efavirenz 600 mg QD x 7 days | Telaprevir AUC: decreased 20%; Cmin: decreased 48% | Tenofovir Cmax: increased 24% | Potentially decreased telaprevir effects | - | Dose adjust telaprevir to 1125 mg Q8H when used with efavirenz. |
| Telaprevir[571](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#571)  (Incivek) | 750 mg Q8H x 7 days | 300 mg QD x 7 days | No significant effect | Tenofovir AUC: increased 30%; Cmin: increased 41%; Cmax: increased 30% | Possibly increased tenofovir effects | - | Dose adjustment not established |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#154)  (TPV)(Aptivus) | 500 mg BID with 100 mg ritonavir BID | 300 mg x 1 dose | Tipranavir Cmin: decreased 21% | Tenofovir Cmax: decreased 23% | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=7&post=4#154)  (TPV)(Aptivus) | 750 mg BID with 200 mg ritonavir BID x 23 doses | 300 mg x 1 dose | No significant change | Tenofovir Cmax: decreased 38% | - | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 3: | Isentress [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; October 2007. |
| 8: | Taburet AM, Piketty C, Gerard L, et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: a substudy of Puzzle2-ANRS 107 trial [abstract #537]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts. |
| 9: | Data on file. Bristol-Myers Squibb Company. Princeton, NJ. |
| 10: | Taburet A-M, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091-96. |
| 12: | Kaul S, Bassi K, Damle B, et al. Lack of interaction between stavudine extended-release formulation and tenofovir disoproxil fumarate [abstract #534]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts. |
| 78: | Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005. |
| 96: | Viread [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2006. |
| 97: | Kearney B, Flaherty J, Sayre J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and lamivudine or didanosine [abstract #337]. 1st International AIDS Society Conference on HIV Treatment and Pathogenesis; 2001 July 8-11th; Buenos Aires, Argentina. |
| 98: | Flaherty J, Kearney B, Wolf J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir or lopinavir/ritonavir [abstract #336]. 1st International AIDS Society Conference on HIV Treatment and Pathogenesis; 2001 July 8-11th; Buenos Aires, Argentina. |
| 102: | Kearney B, Damle B, Plummer A, et al. Pharmacokinetics evaluation of tenofovir DF and enteric-coated didanosine. Sixth International Congress on Drug Therapy in HIV Infection; 2002 November 17-21; Glasgow, United Kingdom. |
| 103: | Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction [abstract #533]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts. |
| 104: | Poirier J, Meynard J, Guiard-Schmid J, et al. Lack of alteration of lopinavir and ritonavir trough plasma concentrations in HIV-experienced patients treated with Kaletra and tenofovir DF. [abstract #H-1715]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois. |
| 123: | Dear Health Care Provider letter. Bristol-Myers Squibb Co., Aug 8, 2003. |
| 124: | Kaul S, Bassi K, Damle B, et al. Pharmacokinetic evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen [abstract #A-1616]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois. |
| 125: | Emtriva [package insert]. Foster City, CA: Gilead Sciences, Inc.; Sept 2005. |
| 126: | Blum MR, Begley J, Zong J, et al. Lack of a pharmacokinetic interaction between emtricitabine and tenofovir DF when coadministered to steady state in healthy volunteers [abstract #A-1621]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois. |
| 135: | Kearney BP, Isaacson E, Sayre J, et al. The pharmacokinetics of abacavir, a purine nucleoside analog, are not affected by tenofovir DF [abstract #A-1615]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois. |
| 136: | Kaul S, Bassi K, Damle B, et al. Stavudine extended release formulation and tenofovir disoproxil fumarate: lack of a pharmacokinetic drug interaction [abstract #602]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California. |
| 142: | Boffito M, Back D, Stainsby-Tron M, et al. Tenofovir does not alter the pharmacokinetics os saquinavir hard gel capsule/ritonavir; data from HIV patients [abstract TuPeB4610]. XV International AIDS Conference; 2004 July 11-16; Bangkok, Thailand. |
| 143: | Bristol-Myers Squibb Company. Potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads. Dear Health Care Provider letter. November 2004. |
| 145: | Zong J, Chittick G, Blum MR, et al. Pharmacokinetic assessment of tenofovir DF and ritonavir-boosted saquinavir in healthy subjexts [abstract A-444]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, D.C. |
| 148: | von Hentig N, Haberl A, Lutz T, et al. Concomitant intake of tenofovir disoproxil fumarate does not impair the plasma exposure of ritonavir-boosted atazanavir in HIV-1 infected adults [abstract PI-40]. American Society for Clinical Pharmacology and Therapeutics; 2005 March 2-6; Orlando, Florida. |
| 149: | Boffito M, Back D, Stainsby-Tron M, et al. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1 infected subjects. Br J Clin Pharmacol 2004; 59: 38-42. |
| 153: | Kurowski M, Walli R, Breske A, et al. Coadministration of tenofovir 300 mg QD with fosamprenavir/ritonavir 1400/100 mg QD or 1400/200 mg QD doses not affect amprenavir pharmacokinetics (COL 20081)[abstact #10]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 April 28-30; Quebec City, Quebec, Canada. |
| 154: | Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005. |
| 155: | Agarwala S, Eley T, Villegas C, et al. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects [abst. 16]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 April 28-30; Quebec City, Canada. |
| 161: | Prezista [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; April 2010. |
| 185: | Smith P, Kearney B, Cloen D, et al. Tenofovir DF does not affect the pharmokinetics or pharmacodynamics of methadone [abst 869]. 2nd International Conference on HIV Pathogenesis and Treatment; 2003 July 13-16; Paris, France. |
| 188: | Smith PF, Kearney BP, Liaw S, et al. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R- and S-methadone. Pharmacother 2004: 24: 970-77. |
| 235: | Kearney BP, Benhamou Y, Flaherty J, et al. Tenofovir pharmacokinetics in hepatic impairment and drug interaction potential with agents used to treat viral hepatitis [abstract #600]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California. |
| 348: | Burger DM, Droste JAH, Kearney BP, et al. Lack of clinically relevant drug-drug interaction between tenofovir DF and rifampin in healthy volunteers [abstract TuPeB4623]. XV International AIDS Conference; 2004 July 11-16; Bangkok, Thailand. |
| 349: | Droste JA, Verweij-van Wissen CP, Kearney BP, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 680-4. |
| 367: | Kearney BP, Isaacson E, Sayre J, et al. Tenofovir DF and oral contraceptives: lack of a pharmacokinetic drug interaction [abstract #A-1618]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois. |
| 391: | Baraclude [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2005. |
| 429: | Scholler-Gyure M, Debroye C, Woodfall B, et al . Pharmacokinetic evaluation of the interaction between TMC125 and tenofovir disoproxil fumarate [poster A-371]. Poster presentation at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-“30, 2006. |
| 430: | Kearney BP and Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacother 2009; 29: 924-29. |
| 443: | Gruber VA, Baker J, Moody DE, et al. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors didanosine, lamivudine and tenofovir [abstract A1-1306]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California. |
| 567: | Edurant [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; May 2011. |
| 569: | Victrelis [package insert]. Whitehouse Station, NJ: Schering Corporation; May 2011. |
| 571: | Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals Inc; May 2011. |
| 641: | Tivicay [package insert]. Research Triangle Park, NC: Viiv Healthcare; Sept 2013. |
| 659: | Sovaldi [package insert]. Foster City, CA: Gilead Sciences; 2013. |
| 679: | Olysio [package insert]. Titusville, NJ: Janssen Therapeutics; 2013. |
| 713: | Harvoni [package insert]. Foster City,CA: Gilead Sciences; 2016. |
| 727: | Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. |
| 747: | Daklinza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2016 |